MCP
VKTX icon

Maso Capital Partners’s Viking Therapeutics VKTX Stock Holding History

Maso Capital Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$657K Buy
25,000
+10,000
+67% +$298K 1.08% 17
2025
Q2 		$398K Buy
+15,000
New +$395K 0.7% 11

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Maso Capital Partners's VKTX Position: Q3 2025 in Review

Maso Capital Partners increased its Viking Therapeutics (VKTX) stake by 67% in Q3 2025, buying an estimated $298K and bringing the position to 25,000 shares worth $657K. The position accounts for 1.08% of the portfolio, ranked #17.

Maso Capital Partners first reported a position in VKTX in Q2 2025 and has held it in 2 quarters since. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Maso Capital Partners held 25,000 shares of Viking Therapeutics worth $657K as of Q3 2025.
  • Maso Capital Partners bought 10,000 Viking Therapeutics shares in Q3 2025, an estimated $298K.
  • Viking Therapeutics made up 1.08% of Maso Capital Partners's portfolio in Q3 2025, its #17 holding.
  • Maso Capital Partners first reported a position in Viking Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Maso Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.